1. 1. Nakagawa K, Kudoh S, Ohe Y, et al. Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 7: 1296-1303, 2012.
2. 2. Gomez R, Harter P, Lück HJ, et al. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer 19: 1284-1287, 2009.
3. 3. Sasaki Y, Kurashima A, Morimoto K, et al. Experience of rapid drug desensitization therapy in the treatment of mycobacterial disease. Kekkaku 89: 797-802, 2014 (in Japanese).
4. 4. Awad MM, Lax TP, Slawski BR, Shaw AT. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. J Thorac Oncol 9: 1726-1728, 2014.
5. 5. Ban GY, Jeong YJ, Lee SH, et al. Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications. Respir Med 147: 44-50, 2019.